Business Wire04.28.17
Corindus Vascular Robotics Inc., a developer of precision vascular robotics, has forged a strategic partnership with BLOXR Solutions, a provider of radiation protection products designed to reduce exposure for clinicians and patients. The three-year distribution agreement grants Corindus the non-exclusive rights to distribute BLOXR's radiation protection products globally and provides BLOXR with additional reach into the interventional cardiology space. Under the agreement, Corindus may sell the entire BLOXR line, which offers multiple types of protective equipment including aprons, thyroid collars and caps.
“Protecting the physicians and staff who care for patients every day is an important part of our mission,” said Mark Toland, president and CEO of Corindus. “We are excited to partner with BLOXR to offer complementary radiation protection products for our cath lab customers around the world.”
Corindus' CorPath System, the first robotic-assisted PCI platform cleared by the U.S. Food and Drug Administration (FDA), has been shown* to reduce radiation exposure to the primary operator by 95 percent1 by positioning them behind a radiation-shielded interventional workstation. Clinical trials with the CorPath System* have also shown a 15 percent2 reduction in radiation exposure for cath lab staff, which can potentially be further enhanced by the addition of the BLOXR line of lightweight protective apparel. BLOXR XPF apparel, which has the potential to further reduce the orthopedic burden for these critical team members, is a patented, comfortable, lightweight material that can be bent and folded without cracking, provides 0.5mm lead equivalent protection and is guaranteed for three years.
“In keeping with our focus of bringing innovation to radiation protection, BLOXR Solutions is excited to make this strategic partnership with Corindus,” said Julia Jacobson, president and CEO of BLOXR Solutions. “Together, we believe we can greatly improve the quality of life for interventional teams by reducing dose exposure, increasing radiation safety, and improving wellness by lessening the potential for occupational injury.”
Corindus Vascular Robotics Inc. develops robotic-assisted vascular interventions. The Waltham, Mass.-based company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures.
References:
1. Weisz, G. et al. Safety and Feasibility of Robotic Percutaneous Coronary Intervention: PRECISE Study. J Am Coll Cardiol. 2013; 61(15):1596-1600.
2. Campbell et al. Staff Exposure to X-ray during PCI: Randomized Comparison of Robotic vs Manual Procedures. Presented at SCAI 2016.
* Studies conducted using CorPath 200 System.
“Protecting the physicians and staff who care for patients every day is an important part of our mission,” said Mark Toland, president and CEO of Corindus. “We are excited to partner with BLOXR to offer complementary radiation protection products for our cath lab customers around the world.”
Corindus' CorPath System, the first robotic-assisted PCI platform cleared by the U.S. Food and Drug Administration (FDA), has been shown* to reduce radiation exposure to the primary operator by 95 percent1 by positioning them behind a radiation-shielded interventional workstation. Clinical trials with the CorPath System* have also shown a 15 percent2 reduction in radiation exposure for cath lab staff, which can potentially be further enhanced by the addition of the BLOXR line of lightweight protective apparel. BLOXR XPF apparel, which has the potential to further reduce the orthopedic burden for these critical team members, is a patented, comfortable, lightweight material that can be bent and folded without cracking, provides 0.5mm lead equivalent protection and is guaranteed for three years.
“In keeping with our focus of bringing innovation to radiation protection, BLOXR Solutions is excited to make this strategic partnership with Corindus,” said Julia Jacobson, president and CEO of BLOXR Solutions. “Together, we believe we can greatly improve the quality of life for interventional teams by reducing dose exposure, increasing radiation safety, and improving wellness by lessening the potential for occupational injury.”
Corindus Vascular Robotics Inc. develops robotic-assisted vascular interventions. The Waltham, Mass.-based company's CorPath System is the first FDA-cleared medical device to bring robotic precision to interventional procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures.
References:
1. Weisz, G. et al. Safety and Feasibility of Robotic Percutaneous Coronary Intervention: PRECISE Study. J Am Coll Cardiol. 2013; 61(15):1596-1600.
2. Campbell et al. Staff Exposure to X-ray during PCI: Randomized Comparison of Robotic vs Manual Procedures. Presented at SCAI 2016.
* Studies conducted using CorPath 200 System.
